Asterion Cannabis announces the appointment of Amy Stephenson, MBA, CFA, CPA, CMA, as Chief Investment Officer.
Asterion Cannabis Inc. (“Asterion” or the “Company”), announces the appointment of Amy Stephenson, MBA, CFA, CPA, CMA, as Chief Investment Officer.
Amy Stephenson has the in-depth cannabis industry knowledge, experience and relationship collateral that allows her to provide relevant information, direction and leadership on optimal financing and public transaction strategies for cannabis companies during the infancy stage. Ms. Stephenson’s addition to the team brings Asterion, one of the most accomplished finance officers in the industry.
Ms. Stephenson has over 20 years of experience in capital markets and managing public companies. Over 15 years were as CFO of public companies focusing on mergers and acquisitions (“M&A”) and IPO/RTO activities in several industries including cannabis, hemp, mining, oil and gas, agriculture, logistics and healthcare. Her involvement in M&A extends beyond Canada to include the United States, Australia, China, Africa and Latin America. Ms. Stephenson was most recently CFO of Cura Cannabis Solutions, Aurora Cannabis, Lineage Growth, The Green Organic Dutchman and Bedrocan, and was instrumental in the Tweed merger with Bedrocan to form Canopy Growth. She also has diversified experience with numerous U.S. cannabis companies and MSOs (Multi-State Operators) involved in cultivation, extractions and edibles.
Ms. Stephenson has an MBA in Finance from California State University, Sacramento. She was a member of the Board and Audit Committee as well as Chair of the Programming Committee of the CFA Society Toronto and, previously, was a non-member (Public) Council and Audit Chair to the Association of Professional Geoscientists of Ontario (APGO) for six years. A regular speaker on mining finance and women, a CFA Charter holder, a Chartered Professional Accountant (CPA, CMA) and a member of the Financial Executive International (FEI).
“We are very pleased to have Amy join our team. Her track record in the cannabis industry, her abilities, and her knowledge is another integral step moving forward to our IPO. Amy will lead the preparation of all IPO material and public financings in preparation for the Company to go public once the capital markets thrive again,” stated Stephen Van Deventer, Chairman and CEO of Asterion.
Amy Stephenson stated, “I am very pleased to join the Asterion team so that I can bring my cannabis experience, from both the U.S. and Canada, to Australia. I have spent much time in Australia in my early career as a corporate development and M&A analyst.”
Asterion Cannabis Inc. is a Canadian medicinal cannabis company with a wholly-owned Australian subsidiary, Asterion (Australia) Pty Ltd. With its cultivation to market strategy, the company’s focus is leading and advancing cannabis agriculture, producing the highest quality, low cost, genetically uniform cannabis strains and cannabinoid products for global supply. The Australian government formally recognizes the company with a Major Project Status and the company has been granted a medicinal cannabis license, a cannabis research license, and a manufacture license from the Australian Office of Drug Control.
Led by a highly experienced team with over 200 years of combined relevant credentials spanning – North America, Europe, the Middle East, and Asia-Pacific. Management experience with large scale projects includes medicinal cannabis, renewable energy, and capital markets.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chief Executive Officer
For further information, please contact:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the construction of the Toowoomba cannabis production facility, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding the Company, including that the Company will be able to obtain the financing and regulatory approvals and licences needed to build the Toowoomba cannabis production facility and to carry out its planned future activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, but not limited to, the inability of the Company (or its Australian subsidiary) to obtain the required approvals and licences for the construction and operation of the Toowoomba cannabis production facility, execute its proposed business plans and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or medical cannabis industry and delays in obtaining governmental and regulatory approvals, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.